Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Spring Bank Pharmaceuticals Inc. Stories

2014-01-28 12:29:36

Seasoned Executive Brings Extensive Track Record of Business and Financial Experience to Clinical Stage Company MILFORD, Mass., Jan. 28, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals today announced that David Arkowitz has been appointed to its Board of Directors. Mr. Arkowitz has more than two decades of finance and operations leadership in the healthcare, life sciences and biotechnology industries. He will help guide Spring Bank's growth with a focus on optimizing the...

2013-11-26 08:28:12

MILFORD, Mass., Nov. 26, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc. of Milford, MA today announced the completion of the single ascending dose portion of their Ph. 1 clinical trial in healthy HCV infected patients and the start of the first cohort of the multiple ascending dose portion of the Phase 1 clinical trial in HCV patients. The trial is being conducted in Australia and New Zealand. The single ascending dose (SAD) stage of the trial was designed to demonstrate the...

2013-10-07 08:26:22

MILFORD, Mass., Oct. 7, 2013 /PRNewswire/ -- Dr. Graham R. Foster and his team from Queen Mary, University of London, London, United Kingdom, will be presenting a poster titled "Pangenotypic anti-HCV activity of SB 9200 assessed in the 'Capture-fusion' replication assay" (Abstract No. 473) at the 64(th) Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Details can now be viewed at the AASLD website at...

2013-05-23 12:26:47

MILFORD, Mass., May 23, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection. This study will be conducted in healthy, HCV-infected patients and is designed to assess both the safety and antiviral efficacy of SB 9200. SB 9200 is a...

2013-02-28 12:27:20

MILFORD, Mass., Feb. 28, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced it has closed on a $10.5 million Series A financing. Proceeds will be used to fund Phase I clinical development of SB 9200, a novel, orally available treatment for Hepatitis C virus (HCV) infection and to further the preclinical pipeline. The Company plans to conduct a Phase I safety and antiviral...

2011-05-05 12:04:00

MILFORD, Mass., May 5, 2011 /PRNewswire/ -- Spring Bank Pharmaceuticals today announced it has been awarded an RO1 grant from the National Institute of Health, National Institute of Allergy and Infectious Diseases for the development of SB 9200, a novel, orally bioavailable agent for the treatment of Hepatitis B virus infection. Under the terms of this award, Spring Bank Pharmaceuticals will receive $3.9 million over five years in support of its development efforts. This is the fourth...

2011-03-03 11:24:00

MILFORD, Mass., March 3, 2011 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc. today announced that Nezam H. Afdhal, M.D. has joined the company as Chair of our Clinical Advisory Board and a member of our Scientific Advisory Board. Dr. Afdhal is a recognized thought leader in the treatment of hepatitis and the development of new antiviral therapies for the treatment of Hepatitis B and C infection. Douglas Jensen, CEO, Spring Bank Pharmaceuticals, stated, "We are very pleased that we...